Lynozyfic could have an edge over rival BCMA-targeting bispecifics.
ApexOnco Front Page
Recent articles
Zegfrovy is approved in a best-case setting, but Dizal has no US presence.
Rusfertide, the subject of a 2024 tie-up, scores in phase 3.
One step forward, two steps back for biotech.
Adcetris bags its eighth approval, while SpringWorks and Ono also feature.
BGB-16673 and BGB-43395 will soon both be in phase 3 trials, BeiGene reveals.
Tough equity markets as well as competitor developments prompt a narrowed focus.
Another SERD catalyst and the son of Darzalex take centre stage.
